GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Price-to-Funds-From-Operations

MEOBF (Mesoblast) Price-to-Funds-From-Operations : (As of Apr. 15, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Mesoblast Business Description

Industry
Traded in Other Exchanges
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.